Fate Of JHL Biotech's Biosimilars Uncertain As Judge Bars Use Of Genentech Trade Secrets
Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.
You may also be interested in...
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.
Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.